Pharmasyntez

Executive Summary

Pharmasyntez, founded in 1997 and headquartered in Irkutsk, is a leading Russian generic pharmaceutical manufacturer specializing in treatments for tuberculosis, HIV/AIDS, and oncology. The company operates five production facilities across Russia and produces both finished dosage forms and active pharmaceutical ingredients (APIs). With a focus on affordability and accessibility, Pharmasyntez serves the Russian healthcare system and aims to reduce dependency on imported medicines. Its product portfolio includes essential generics for infectious diseases and cancer, positioned to benefit from Russia's import substitution policies and increasing domestic demand for cost-effective therapies.

Upcoming Catalysts (preview)

• Q3 2026Launch of new oncology generic (e.g., biosimilar or complex generic) in Russia60% success
• Q1 2027WHO prequalification or stringent regulatory approval for a tuberculosis API50% success
• 2026Expansion of API production capacity to support export growth70% success